Genentech cancer med nabs Breakthrough status

Share this article:

Roche subsidiary Genentech scored a breakthrough-therapy designation for its experimental Phase-I immuno-oncology drug MPDL3280A. The anticipated patient population is comprised of previously treated metastatic urothelial bladder cancer patients who test positive for PD-L1, which stands for programmed death ligand-1. The test is being developed by parent company Roche.

Genentech said in a statement Saturday that results prompting the FDA's breakthrough label showed tumors shrank in 43% of patients.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.